Bioneer

Big Science Facilities Bioneer is part of a network involving Technological Institute, FORCE Technology and Alexandra Institute both acting as a mediator for companies and researches that wants to access neutron –and X-Ray facilities and additionally also complete demonstrator projects involving the use of these facilities within different fields. Bioneer:FARMA will complete demonstrator projects focusing SAXS/sSAXS and SANS/sSANS based analysis of drug formulations. The Bioneer:FARMA group is located at the Department of Pharmacy at the University of Copenhagen and has access to all instruments and technologies essential for pharmaceutical R&D programs. Protein Manufacturing Bioneer has actively been developing and refining protein manufacturing technologies including downstrean and upstream technologies. Bioneer has developed microbial production tools (vectors) as well as hosts and synthetic cultivation media. For 18 years Bioneers P170 system which is based on L. lactis has proven its value especially for manufactuing of vaccine candidates. Furthermore, 6 years ago Bioneer developed an effective E. coli based production platform (E-c) which is popular among clients. Bioneer also exploits mammalian cell systems (CHO, HEK) for manufacturing. Current research activities are aiming at increasing the productivity of microbial strains by engineering specific DNA elements. With respect to increasing the productivity of mammalian cells we are investigating engineering technologies as well as cultivation techniques. Predictive 3D Cell Models Our current R&D program within Predictive 3D Cell Models will use three-dimensional (3D) cell culture technologies to design and generate highly relevant models for liver toxicity and cancer models for investigating Mode-of-Action of cancer drug candidates. 3D Bioprinting will be implemented as a key technology to generate highly reproducible 3D models relevant for industrial use. The R&D groups involved in the activities of Predictive 3D Cell Models are located both at the Bioneer:FARMA unit at the Department of Pharmacy at University of Copenhagen in Copenhagen as well as the Bioneer headquarter facilities in Hørsholm. Thus, having access to all central infrastructure, instruments and technologies essential for the pharmaceutical R&D programs including the gene editing and iPSC core facility. Microbiome in Health and Disease Our current R&D program within the Microbiome field focuses on the development of new culture processes for microbiome strains releasing the full potential of testing and producing such strains in a larger scale. To be able to investigate Mode of Actions of microbiome strains and probiotics, we will develop relevant human cell model systems, e.g. immune models and intestinal models, that in addition will be used for evaluation the interactions between the microbiome and drug substances. The R&D groups involved in the Microbiome activities are located both at the Bioneer headquarter facilities in Hørsholm and at Bioneer:FARMA located in Copenhagen, ensuring access to key instruments and a broad palette of analytical equipment essential for the R&D program.